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Stroma is a largely understudied component of all organs that contributes to stem cell niches. Studies to
define stromal components in the bone marrow have led to some unexpected findings that prompt further
research.Search ‘‘stroma’’ and until last year or so,
what popped up first in Wikipedia was
‘‘an island off the northern coast of Scot-
land.’’ But who can blame the Wiki writers
when most biologists would have trouble
getting beyond connective tissue and
vessels? It is a grab-bag term that reflects
a lack of precise determination of com-
ponents and functions because there has
been little detailed investigation. Here,
I argue that in this era when we know
the sequence of every human gene, it is
unreasonable to accept persistent ambi-
guity of stromal cellular and extracellular
constituents: not just because stroma is
present in virtually every human organ,
but because stroma is central to tissue
homeostasis, repair, and disease.
Stroma entered the biologic vernacular
in the 19th century as microscopists
viewed tissues and saw parenchymal
cells embedded in a supportive frame-
work. The framework received the name
in Latin for a mattress, stroma. It is often
interchangeably used with mesenchyma,
which is the structural part of a tissue in
support of the functional parenchyma.
Parenchyma in Greek is literally the
‘‘visceral flesh’’ that as a verb is ‘‘poured
in’’ to mesenchyma. That mesenchyma
would be viewed as relatively inert
support for early microscopists is not
surprising, yet it has long been known to
be critical for developing tissues.
Mesenchymal interactions with epithe-
lial parenchyma are essential for organo-
genesis. Mesenchymal cells emerge
during gastrulation and become a part
of virtually every tissue of metaozoans.
They participate in key patterning
events determining with precision the
identity, number, and organization of
cells comprising developing organs and
appendages. For example, epithelial-
mesenchymal signaling feedback loops648 Cell Stem Cell 10, June 14, 2012 ª2012involving sonic hedgehog (Shh) and FGF
are critical for limb development (Be´nazet
et al., 2009). Specialized regions of
mesenchymal cells form the dermal
papillae that regulate hair follicle morpho-
genesis by b-catenin signaling altering
FGF and IGF production (Enshell-Seijffers
et al., 2010). Branching morphogenesis,
important in multiple organ types, is in
part controlled by mesenchymal cell
islands producing FGF10 in a Shh-regu-
lated manner (Affolter et al., 2003). Yet, in
the homeostasis of adult tissues, these
critical functional aspectsofmesenchymal
cells are generally regarded as vestigial
and it has only recently been made clear
that mesenchyma and stroma are more
than architectural support elements.
Mesenchymal stromal cells are increas-
ingly appreciated to be heterogeneous,
dynamic, and play a regulatory role in
parenchymal cell function in adult tissues.
This is evident in the regulatory environ-
ment for stem/progenitor cells, particu-
larly in hematopoiesis, and hematopoiesis
will be the sole focus hereafter for sake of
brevity, though other tissues have been
studied by others.
The stroma of bone marrow has histor-
ically been a focus in hematopoiesis
research, at least in part due to the limited
ability to maintain or grow hematopoietic
stem cells outside the body. Michael
Dexter first demonstrated the importance
of stroma in coculture experiments that
established the now classic method for
in vitro hematopoietic stem/progenitor
cell (HSPC) support (Dexter et al., 1977).
His laboratory neighbor at the University
of Manchester, Raymond Schofield,
observed the variable stem cell properties
of the spleen colony-forming unit when
cultured in isolation and proposed that
stroma was also of critical importance
in vivo, providing a stem cell ‘‘niche’’Elsevier Inc.(Schofield, 1978), a term he coined in
his landmark paper.
While the hematopoietic cells that
represent the parenchyma of bone
marrow are the primary interest, it is the
stroma that has become a highly promi-
nent focus for trying to understand the
behavior of the hematopoietic cells in
both health and disease. The stroma is
seen as the critical piece, still veiled, that
drives the physiology of the hematopoi-
etic stem cell.
In 2003, both my laboratory and that of
Liheng Li first reported the presence of
regulatory cells in the stroma using in vivo
genetic models (reviewed inMercier et al.,
2012). There are now more than 1,000
papers on the topic according to Scopus.
What that work has shown is that the
participating parts of the stroma are highly
complex, far more complex than the first
naive reports suggested or than inverte-
bratemodels suggested. The invertebrate
model of a single cell type governing
a single stem cell type is not the case in
the bone marrow and likely not in other
tissue niches as well. Neural and nonmye-
linating Schwann cells, endothelial cells,
and mature hematopoietic cells like
macrophages and possibly osteoclasts
all participate in regulating HSPCs (re-
viewed inMercier et al., 2012). Evenwithin
the mesenchymal cell pool, multiple
candidate populations have evidence of
modifying HSPC number, quiescence,
and/or localization including those ex-
pressing CXCL12, osterix, Nestin, leptin
receptor, adipocyte markers, and,
perhaps, N-cadherin (reviewed in Mercier
et al., 2012). This level of complexity in cell
type has created ongoing efforts to
discern the overlap or distinction among
mesenchymal cells and to organize
participants hierarchically, for example,
which cell type matters in terms of kit
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addition, it is becoming clear that there
is heterogeneity in stem cells and the
pairing of stem cell type and niche cell
type is undefined. Rationally defining the
relationships between cell types and the
molecules they produce will require
a cataloging process that is likely to take
years but offers the potential of giving at
least a snapshot view of participants in
the orchestra. What will we have at the
end? It may well be an assembly without
sufficient annotation to know what nodal
point can be tweaked to modify how the
system behaves as a whole. Returning
to the orchestra analogy, we will know
who is in the chairs and maybe even
what instruments they can play, but we
will not know how to make music. That
would take more of a systems biology
approach, investigating multiple compo-
nents simultaneously over time to define
just how the components are hierarchi-
cally related and integrate their activity
to provide physiologic outputs.
Such a systems-like approach would
be enormously demanding in time and
resources that could only be worth it if
highly distinctive applications might
result. The possibility of distinctive appli-
cations is suggested by unexpected
outcomes of experimental work noted
below that was initially intended to
address other questions.
Dexter taught that stroma was needed
to keep cells happy ex vivo and investiga-
tion into the niche that followed generally
focused on assessing what is needed
for homeostasis. However, perturbing
stromal cells resulted in odd hematopoi-
etic phenotypes in at least two instances.
For example, genetic perturbations of pri-
mitive mesenchymal cell subsets (altering
RNA processing or ribosomal genes) or
more undefined populations (deleting
RARg) disordered the regulatory environ-
ment of the hematopoietic system suffi-
ciently to cause a dysplastic and frank
malignant state or a hyperproliferative
one, respectively (Raaijmakers et al.,
2010; Walkley et al., 2007). This disorgani-
zation of the hematopoietic parenchyma
by mesenchymal dysfunction reveals how
critical the relationships are. Those rela-
tionships do not just maintain the localiza-
tion or number of parenchymal stem cells,
but also the integrity of parenchymal orga-
nization and function.Moreover, the effect
was driven by particular mesenchymalcells. Cells expressing osterix altered
hematopoietic function, while those ex-
pressing osteocalcin did not (Raaijmakers
et al., 2010). Perhaps most interesting
about the parenchymal malignancy (acute
myeloid leukemia) arising in one of the
studies (Raaijmakers et al., 2010) is that
molecular characterization of the few
leukemias that could be studied indicated
that they had multiple, new genetic
lesions. These data argue that the alter-
ation of stromal function imposes a new
set of rules on the parenchymal cells. It
changes the way they function, as evident
in dysplasia, and it changes what cells
thrive. The emergence of malignant cells
was presumably due to selection: a selec-
tion that seemed to be persistent when
the cells were secondarily transplanted.
Altered stroma may impose new determi-
nantsof ‘‘fitness’’ on theparenchymal cells
withwhich it interacts. It could then enable
and perhaps facilitate outgrowth of a
neoplastic clone. This model would argue
that the multihit hypothesis of cancer
could include a hit outside of the cancer
cell itself: a cell nonautonomous partici-
pant in the emergence of malignancy.
Stroma participating in the invasive-
ness or growth characteristics of malig-
nancy is a longstanding concept about
which much has been published, but
amodel whereby it can be a primary driver
of cancer emergence adds a different
dimension and enhances the rationale
for learning more about just what stroma
is and how it works. This is further fueled
by the recent recognition that osteoline-
age cells participating in bone marrow
stroma are highly dynamic (Park et al.,
2012). They turn over with rapidity not
unlike the hematopoietic system and
they are replaced by a stem/progenitor
pool much like other tissues of rapid cell
turnover. Further, the cells can translo-
cate both interstitially and intravascularly
so they could theoretically be a population
that could acquire a genetic lesion, and
propagate that lesion to a large number
of descendent cells and distant sites.
They could create a ‘‘field’’ of stroma
imposing different selection pressures
on parenchymal cells. Such a scenario
may not be a commonplace basis for
neoplasia emerging, but it raises the issue
of whether stroma might change with age
in a way in which acquired genetic lesions
within parenchymal cells might be given
a competitive edge, providing them aCell Stem Cellniche in which previously they would not
have thrived. It is a hypothesis worth test-
ing particularly as it might provide insight
into new vulnerabilities of cancer cells.
If stroma is a part of the ecosystem in
which cancer emerges, understanding
how its dysfunction could lead to the
selection of malignant cells raises another
possibility. There are few settings where
cancer biology focused on the cancer
cell as an autonomous unit have provided
opportunities for prevention. Perhaps
defining how targeted alterations in
specific stromal cells select for dysplastic
and neoplastic cells will offer such an
opportunity. Even the somewhat odd
models such as those cited above may
give us insight into the signals at work
between mesenchymal and parenchymal
cells that enable a malignant prone condi-
tion to proceed.
Stroma has shown itself in the bone
marrow to be far more than just the stuff
that holds tissues together and it may
hold greater secrets still. Teasing stroma
apart in other tissues as well as bone
marrow, testing its components as
disease participants, and defining
whether it can be therapeutically targeted
is worth our attention, particularly in the
context of tissue stem cells.
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